#SFHS2608371AOrder of April 8, 2026, amending the list of pharmaceutical specialties reimbursable to social insureds
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates France's list of medicines that can be reimbursed to patients by social insurance. Specific treatment options for moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease are now reimbursable. This affects both adults and children under certain medical conditions when other treatments are inadequate or not tolerated.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Includes new reimbursable medicines for plaque psoriasis, psoriatic arthritis, and Crohn's disease
- Covers both adult and pediatric cases under specific conditions
- Focused on treatments inadequate or intolerable by other means
Obligations
What this law requires
Update the list of reimbursable pharmaceutical specialties (list des spécialités pharmaceutiques remboursables) to include YESINTEK 45 mg and YESINTEK 90 mg (ustekinumab) as specified in the Annex
Reimburse YESINTEK (ustekinumab) only for moderate to severe plaque psoriasis in adults when there has been failure, contraindication, or intolerance to other systemic treatments including ciclosporine, methotrexate, or PUVA therapy
Reimburse YESINTEK (ustekinumab) for psoriatic arthritis treatment in adults only when used alone or with methotrexate and when response to prior non-biological DMARD treatment was inadequate
Reimburse YESINTEK (ustekinumab) for moderate to severe active Crohn's disease in adults only when patients have failed conventional treatment (corticosteroids or immunosuppressants) and at least one anti-TNFα treatment, or have contraindications to these treatments
Reimburse YESINTEK (ustekinumab) for moderate to severe plaque psoriasis in children and adolescents aged 6 years and older only when there is insufficient response or intolerance to other systemic treatments or phototherapies